NEWS
23
2026-07
Amlodipine Besylate API Approved for Marketing!
Newland Pharmaceutical's Amlodipine Besylate API has received NMPA marketing approval, marking another step forward in the company's cardiovascular API portfolio.
19
2026-07
Set Benchmarks · Embark Anew | Newland Pharma Amoeba Management Phase I Commendation & Training Conference Concludes Successfully
On July 18, Xintiandi Pharma held the Phase I commendation and training activity for the Amoeba Management Project in the multi-functional lecture hall on the third floor of the company. The event was attended by the company’s middle and senior management personnel, all Amoeba leaders, and senior consultants from Bomington Consulting. Centering on phased work summary, outstanding employee recognit
06
2026-07
Meet Newland in Bangkok | CPHI Southeast Asia 2026
Join us at Booth L49 to explore new opportunities in the ASEAN pharmaceutical market and discuss potential partnerships.
23
2026-06
Levamlodipine Besylate API Approved for Marketing!
Newland Pharmaceutical's Levamlodipine Besylate API is now approved for marketing by the NMPA.
PRODUCTS
COMPANY PROFILE
We are one of the early domestic manufacturers
engaged in the research, development and production of L-4-Hydroxyphenylglycine and its derivatives. All technical and quality indicators of our products have reached international standards.
CORPORATE CULTURE
The company has established a scientific human
resource management system and a competitive compensation system. Focusing on internal equity, we give full play to the incentive function of salary and benefits.
COMPANY HONOR
The company is a National High-tech Enterprise, a
Key Enterprise under the support of the Ministry of Commerce, a Key Enterprise for the Export of High-tech Products in Henan Province, a Pilot Innovation Enterprise of Henan Province,
Contact Us
Tel: +86 138 1600 0664
Email：dma@newlandpharma.com
Address：Changning District, Shanghai China
Follow Us
